cancer
world
main
public
health
problem
also
main
caus
death
whole
world
basi
globocan
million
cancer
case
detect
million
death
occur
worldwid
usa
new
cancer
case
cancer
death
project
occur
although
disturb
number
indic
war
cancer
recent
develop
anticanc
drug
higher
inhibitori
activ
strong
select
structur
modif
natur
product
etoposid
teniposid
vindesin
vinorelbin
deriv
vinca
alkaloid
epipodophyllotoxin
rais
hope
cancer
patient
surviv
today
use
lot
drug
indirectli
directli
deriv
natur
product
structur
modif
natur
product
pharmacolog
activ
obtain
anticanc
drug
high
inhibitori
activ
select
becom
popular
research
direct
fructu
ligustri
lucidi
natur
product
fruit
ligustrum
lucidum
ait
tradit
chines
medicin
fructu
ligustri
lucidi
discov
use
earli
treatment
variou
diseas
oleanol
acid
oa
pentacycl
triterpenoid
compound
isol
fructu
ligustri
lucidi
research
show
strong
interest
investig
oa
extens
biolog
activ
antiviru
antitumor
antiinflammatori
pharmacolog
activ
glycyrrhetin
acid
ga
natur
product
extract
glycyrrhiza
uralensi
ga
oa
similar
structur
pentacycl
triterpenoid
compound
figur
ga
also
antitumor
antiinflammatori
antivir
antiallerg
antiulc
activ
studi
found
oa
ga
broad
inhibitori
effect
growth
mani
tumor
cell
line
vitro
induc
tumor
cell
autophagi
apoptosi
block
cell
cycl
inhibit
multidrug
resist
tumor
explor
physiolog
activ
oa
ga
research
perform
larg
number
structur
modif
studi
biolog
activ
two
natur
product
previou
report
think
structur
modif
improv
anticanc
activ
oa
ga
appropri
chu
et
al
report
first
prepar
ligustrazineoleanol
acid
introduct
amino
acid
fragment
obtain
new
compound
high
inhibitori
activ
li
et
al
report
first
prepar
ga
ester
introduct
propano
acid
fragment
greatli
improv
anticanc
activ
compar
ga
research
use
method
combin
prepar
oa
ga
ester
increas
lipophil
introduc
organ
acid
group
increas
polar
select
kind
organ
acid
nicotin
acid
acid
acid
cinnam
acid
isonicotin
acid
salicyl
acid
acetyl
acid
acetylsalicyl
acid
acetyl
acid
acetyl
acid
certain
biolog
activ
posit
oa
ester
ga
ester
final
synthes
new
oa
ga
deriv
new
compound
target
product
use
five
cancer
cell
line
hela
determin
antitumor
activ
human
skin
fibroblast
hsf
control
solvent
reagent
use
experi
bought
xinyu
chemic
glass
co
weihai
china
without
purif
oa
ga
bought
tianjin
heown
biochem
technolog
co
ltd
tianjin
china
without
purif
cell
line
bought
shanghai
institut
cellular
biolog
chines
academi
scienc
cand
hnmr
spectra
obtain
instrument
mhz
use
cdcl
solvent
highresolutionelectrospray
ionizationmass
spectra
hresim
record
ltq
orbitrap
mass
spectromet
sgw
micromelt
point
apparatu
use
measur
melt
point
mp
thinlay
chromatographi
tlc
column
chromatographi
perform
silica
gel
plate
silica
gel
synthesi
compound
gener
experiment
method
synthesi
b
mmol
anhydr
potassium
carbon
mg
mmol
n
ndimethylformamid
dmf
ml
stir
min
ml
benzyl
bromid
mmol
ad
mixtur
stir
h
reaction
first
satur
sodium
chlorid
ml
ad
extract
carri
ethyl
acet
organ
phase
wash
water
dri
anhydr
magnesium
sulfat
follow
suction
filtrat
concentr
obtain
target
compound
gener
experiment
method
synthesi
b
b
b
one
millimol
r
oh
r
oh
gener
experiment
way
synthesi
g
n
dmf
ad
solut
nicotin
acid
isonicotin
acid
mol
socl
ml
min
mixtur
slowli
heat
stir
reflux
h
excess
socl
distil
reduc
pressur
obtain
white
acid
chlorid
product
anhydr
dichloromethan
solut
ml
drug
design
develop
therapi
submit
manuscript
wwwdovepresscom
dovepress
dovepress
cytotox
properti
oa
ga
deriv
mmol
mix
white
acid
chlorid
product
well
et
n
mixtur
stir
room
temperatur
tlc
use
monitor
reaction
progress
reaction
mixtur
wash
satur
sodium
bicarbon
solut
satur
sodium
chlorid
solut
organ
layer
dri
anhydr
na
filter
filtrat
concentr
get
yellow
solid
target
product
purifi
column
chromatographi
ethyl
obtain
g
n
white
solid
anoth
experiment
way
synthesi
b
compound
mmol
dissolv
pyridin
ml
anhydr
acet
anhydrid
ml
ad
stir
room
temperatur
h
reaction
complet
mixtur
pour
icecold
dilut
hydrochlor
acid
kept
overnight
afterward
mixtur
filter
wash
moll
hydrochlor
acid
remov
pyridin
wash
water
neutral
dri
anhydr
sodium
sulfat
organ
layer
filter
filtrat
concentr
get
yellow
solid
latter
purifi
column
chromatographi
ethyl
give
white
solid
spectroscop
result
consist
b
test
compound
dissolv
suitabl
amount
dimethyl
sulfoxid
prior
experi
obtain
known
concentr
solut
solut
dilut
variou
concentr
cultur
medium
evalu
cytotox
activ
gastric
cancer
breast
cancer
esophag
cancer
hela
cervic
cancer
hepatoma
cancer
cell
line
cellsml
hsf
normal
hsf
cellsml
place
plate
cultur
h
presenc
co
atmospher
h
incub
cultur
medium
discard
cell
treat
test
compound
variou
concentr
h
control
group
treat
medium
alon
mtt
solut
mgml
ad
well
incub
anoth
h
medium
aspir
formazan
crystal
dissolv
dimethyl
sulfoxid
well
absorb
measur
test
wave
length
nm
use
biorad
micropl
reader
ic
valu
obtain
linear
regress
analysi
use
graphpad
prism
version
cell
seed
sixwel
plate
cultur
dmem
supplement
fetal
bovin
serum
fb
incub
co
h
medium
replac
medium
contain
differ
concentr
compound
h
cell
apoptosi
assay
use
pe
annexin
v
apoptosi
detect
kit
bd
bioscienc
accord
manufactur
instruct
cell
digest
trypsinedta
solut
wash
twice
cold
pb
stain
annexin
vpe
bind
buffer
incub
room
temperatur
min
cell
apoptosi
analyz
bd
fac
aria
iii
flow
cytomet
cell
seed
sixwel
plate
cultur
dmem
supplement
fb
incub
co
h
medium
replac
medium
contain
differ
concentr
compound
h
medium
remov
wash
cold
pb
fix
formalin
wv
cell
nuclei
counterstain
hoechst
concentr
pb
min
dark
final
cell
wash
twice
cold
pb
examin
fluoresc
microscop
cell
seed
sixwel
plate
cultur
dmem
supplement
fb
incub
co
h
medium
replac
medium
contain
differ
concentr
compound
h
medium
remov
cell
wash
icecold
pb
twice
cell
stain
monodansylcadaverin
mdc
solut
mm
min
wash
twice
pb
data
obtain
flow
cytometri
shown
scheme
oa
deriv
name
synthes
esterif
oa
perform
treatment
benzyl
bromid
produc
oa
ester
organ
acid
r
oh
coupl
posit
obtain
ester
use
dmapedci
system
nicotin
acid
isonicotin
acid
dissolv
socl
triethylamin
ad
obtain
synthesi
ga
deriv
describ
scheme
treatment
ga
benzyl
bromid
presenc
k
co
give
ga
ester
posit
react
organ
acid
r
oh
edcidmap
system
form
compound
treatment
nicotin
acid
isonicotin
acid
socl
follow
addit
triethylamin
acidbind
agent
use
esterif
procedur
obtain
compound
n
compound
b
b
b
prepar
shown
scheme
studi
report
ester
acetylsalicyl
acid
easili
undergo
ester
exchang
reaction
thu
acetylsalicyl
acid
react
b
edci
dmap
system
obtain
b
rather
b
shown
possibl
reaction
mechan
figur
high
nucleophil
dmap
contribut
nucleophil
addit
ester
moieti
acetylsalicyl
acid
form
intermedi
convert
nacylpyridinium
intermedi
elimin
phenoxid
anion
afterward
nacylpyridinium
salt
nucleophil
attack
hydroxyl
moieti
b
produc
intermedi
ii
neutral
situ
form
phenoxid
anion
follow
remov
dmap
transform
desir
ester
attempt
obtain
b
b
treat
b
acetyl
acid
acetyl
acid
edcidmap
system
treatment
b
acetyl
acid
inde
allow
prepar
b
almost
get
byproduct
interestingli
main
product
obtain
result
interact
acetyl
hydroxybenzo
acid
b
b
instead
b
vitro
cytotox
activ
compound
b
b
b
b
b
evalu
vitro
cytotox
hela
hsf
cell
consid
literatur
relat
studi
use
micromolar
studi
cytotox
oa
ga
deriv
research
use
micromolar
studi
cytotox
compound
b
b
b
b
b
antitumor
activ
express
term
ic
summar
tabl
whole
ga
deriv
better
cytotox
oa
deriv
parent
compound
oa
ga
show
low
inhibitori
activ
cell
cell
hsf
cell
ga
better
cytotox
valu
gefitinib
cell
cell
hela
cell
especi
cell
ic
valu
oa
show
poor
inhibitori
effect
three
cell
line
contrast
oa
ga
esterifi
compound
benzyl
group
exhibit
rel
high
inhibitori
activ
cell
cell
cell
indic
benzyl
group
introduc
posit
oa
posit
ga
benefici
improv
inhibitori
activ
cancer
cell
select
inhibitori
activ
compound
significantli
enhanc
oa
modifi
compound
show
strong
inhibitori
activ
cell
poor
inhibitori
effect
hsf
cell
result
consist
test
result
novel
ligustrazineoleanol
acidamino
acid
deriv
synthes
chu
et
al
r
group
butyroxi
longchainsubstitut
compound
ic
significantli
stronger
inhibitori
activ
cell
acetoxi
shortchainsubstitut
compound
ic
introduc
salicyloyloxi
posit
led
signific
increas
select
inhibitori
activ
low
ic
valu
cell
hsf
cell
exhibit
poor
inhibitori
effect
high
ic
valu
addit
heteroaroyl
group
posit
also
present
superior
activ
cell
surprisingli
compound
bear
aco
group
differ
locat
present
strong
inhibitori
activ
hela
cell
compound
oaco
substitut
ic
aromat
ring
activ
compound
paco
substitut
ic
result
modif
ga
compound
exhibit
differ
anticanc
activ
compound
display
poor
inhibitori
effect
five
kind
cancer
cell
indic
organ
acid
moieti
introduc
posit
benefici
enhanc
inhibitori
activ
compound
exhibit
strongli
select
inhibitori
activ
particular
compound
show
strongest
inhibitori
activ
hela
cell
ic
valu
suggest
aco
substitu
might
enhanc
toward
tumor
cell
line
compound
present
potenti
anticanc
activ
comparison
gefitinib
compound
activ
one
indic
heteroaroyl
introduc
posit
benefici
enhanc
inhibitori
activ
cytotox
deriv
obtain
schwarz
csuk
introduct
amino
acid
posit
ga
benzyl
ester
consist
present
result
furthermor
inhibitori
activ
compound
hsf
cell
lower
gefitinib
ic
addit
aco
group
posit
show
superior
inhibitori
activ
tumor
cell
line
especi
cell
ic
valu
yadav
et
al
use
quantit
structureact
relationship
qsar
model
predict
compound
signific
inhibitori
effect
cell
experiment
result
consist
predict
like
compound
compound
also
present
strong
target
inhibit
hela
cell
ic
valu
respect
summari
although
structur
oa
ga
similar
deriv
exhibit
differ
anticanc
activ
anticanc
activ
differ
even
group
introduc
anoth
import
find
introduct
pyridin
ring
lower
electron
densiti
posit
ga
benzyl
ester
compound
could
greatli
increas
anticanc
activ
furthermor
incorpor
carbonyl
group
electronwithdraw
properti
posit
ga
benzyl
ester
compound
also
could
greatli
improv
anticanc
activ
therefor
tri
sum
conclus
follow
ga
first
convert
benzyl
ester
ga
electronwithdraw
group
introduc
posit
benzyl
ester
ga
could
greatli
improv
anticanc
activ
ga
conclus
also
appli
oa
introduct
electronwithdraw
group
posit
benzyl
ester
oa
compound
could
also
significantli
improv
anticanc
activ
oa
given
show
high
antiprolif
activ
cell
use
cell
studi
mechan
action
shown
figur
present
signific
effect
inhibit
cell
growth
inhibit
cell
prolifer
concentrationand
timedepend
manner
figur
also
show
cell
die
treatment
h
apoptosi
necrosi
especi
former
common
cellular
respons
anticanc
drug
evalu
whether
cytotox
effect
relat
apoptosi
detect
cell
apoptosi
hoechst
apoptot
stain
kit
detect
apoptosi
rate
annexin
doubl
stain
method
figur
treatment
differ
concentr
control
compound
h
nuclei
cell
stain
hoechst
detect
apoptot
cell
shown
figur
compar
control
group
larg
number
cell
blue
light
spot
observ
test
group
dosedepend
manner
result
indic
exist
induc
apoptosi
caus
treatment
compound
use
annexin
dual
stain
detect
earli
late
apoptosi
cell
treat
differ
concentr
compound
h
shown
figur
popul
apoptot
cell
treat
compound
increas
remark
doseand
timedepend
relat
percentag
annexin
vposit
cell
control
group
h
treatment
control
group
h
treatment
autophagi
lysosom
degrad
pathway
consid
third
mode
cell
death
besid
cytotox
properti
oa
ga
deriv
apoptosi
necrosi
essenti
homeostasi
normal
condit
determin
whether
autophagi
truli
trigger
deriv
cell
treat
compound
h
cell
stain
mdc
fluoresc
probe
detect
autophag
activ
shown
figur
studi
base
principl
combin
simpl
twostep
synthet
method
design
synthes
seri
oa
ga
test
cytotox
mtt
assay
hela
hsf
cell
among
oa
ga
deriv
compound
activ
anticanc
agent
cell
ic
respect
show
lower
inhibitori
activ
normal
hsf
gefitinib
cell
compound
show
best
cytotox
effect
ic
pharmacolog
evalu
show
compound
could
induc
autophagi
apoptosi
cell
addit
compound
exhibit
strongest
inhibitori
activ
hela
cell
ic
comparison
four
cancer
cell
line
present
low
cytotox
toward
hsf
cell
ic
strong
select
inhibit
may
potenti
new
antihela
candid
drug
uniqu
mechan
action
deserv
studi
like
compound
compound
present
superior
select
inhibitori
activ
cell
ic
comparison
four
cancer
cell
line
also
present
low
cytotox
toward
hsf
cell
ic
may
potenti
new
candid
drug
uniqu
mechan
action
also
deserv
studi
submit
manuscript
http
wwwdovepresscomdrugdesigndevelopmentandtherapyjourn
drug
design
develop
therapi
intern
peerreview
openaccess
journal
span
spectrum
drug
design
develop
clinic
applic
clinic
outcom
patient
safeti
program
develop
effect
safe
sustain
use
medicin
featur
journal
also
accept
index
pubm
central
manuscript
manag
system
complet
onlin
includ
quick
fair
peerreview
system
easi
use
